Eli Lilly and Company
Explore Eli Lilly and Company
Core profile pages, annual revenue records, and related research hubs for this company.
CorpDigest
Eli Lilly and Company
Explore Eli Lilly and Company
Core profile pages, annual revenue records, and related research hubs for this company.
Annual Revenue
FY2024 Revenue
$45.0B
▲ 31.9% vs FY2023 ($34.1B)
Net Income: $10.6B
Source: Annual report / company filing
Eli Lilly and Company reported $45.0B in revenue for fiscal year 2024. This represents a growth of 31.9% compared to the 2023 figure of $34.1B. In 2025, revenue increased to $65.2B.
Revenue surged 31.9 percent to $45.0 billion in 2024, driven by roughly $13.9 billion in combined Mounjaro and Zepbound sales alongside Kisunla's Alzheimer's approval.
| Year | Revenue | Net Income | YoY Change |
|---|---|---|---|
| FY2025 | $65.2B | — | +44.8% |
| FY2024 | $45.0B | $10.6B | +31.9% |
| FY2023 | $34.1B | — | +19.6% |
| FY2022 | $28.5B | — | +0.8% |
| FY2021 | $28.3B | — | +15.5% |
| FY2020 | $24.5B | — | — |
Source: SEC EDGAR filings, annual earnings releases, and verified financial disclosures.